Study of CoQ10 During One Cycle of Doxorubicin Treatment for Breast Cancer

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Basic Trial Information

PhaseTypeStatusAgeSponsorProtocol IDs
Phase ISupportive care, TreatmentActive21 and overNCI, OtherAAAD8521

Trial Description


This research study hopes to examine the effects of Coenzyme Q10 on doxorubicin (Adriamycin) metabolism during breast cancer treatment. Doxorubicin is a lifesaving breast cancer treatment.

However, approximately 3-20% of women who receive doxorubicin treatment experience some damage to their heart muscle. Coenzyme Q10 is a fat soluble antioxidant dietary supplement that may protect against this heart damage during doxorubicin treatment. It is unknown how Coenzyme Q10 may interact with doxorubicin. This study will assess the effects of Coenzyme Q10 on doxorubicin metabolism.

Further Study Information

This is a phase I randomized, placebo-controlled, cross-over pharmacokinetic and dose-finding study to assess the safety of CoQ10 during doxorubicin treatment for breast cancer in a maximum of 18 patients. Safety will be assessed by measuring 1) intra-patient differences in doxorubicin and its active metabolites, with and without CoQ10, and 2) adverse events. We hypothesize that CoQ10 administration during doxorubicin treatment is safe and will not affect doxorubicin active metabolites. Using three dose levels of CoQ10, the maximum tolerated dose (MTD) will be determined by assessing change in doxorubicin concentration (area under the curve (AUC), change in peak concentration levels (Cmax)), and adverse events.

Eligibility Criteria

Inclusion Criteria:

  • Diagnosis of early stage breast cancer (stage I, II, or III);
  • Scheduled to receive at least four rounds of dose dense doxorubicin therapy in the neoadjuvant or adjuvant setting;
  • No other history of prior chemotherapy, radiation, or hormonal therapy in the previous 5 years;
  • For women receiving adjuvant therapy, single lumen implanted venous access device (i.e. single port) for unilateral cancer and double lumen implanted venous access device (i.e. double port) for bilateral breast cancer
  • Age 21 years or older;
  • ECOG performance status ≤ 2 (Karnofsky > 60%);
  • Normal organ and marrow function defined as: Leukocytes ≥ 3,000/uL, Absolute neutrophils count (ANC) ≥ 1,500/uL at baseline, Platelets ≥ 100,000/uL, Total bilirubin ≤ 1.5 X normal institutional limits, AST (SGOT)/ALT (SGPT) ≤ 2.5 X institutional ULN, Serum creatinine within normal institutional limits;
  • Left ventricular ejection fraction > 55%;
  • No history of CoQ10 supplement use within 30 days of initiating study drug;
  • No uncontrolled or significant co-morbid illness;
  • Not pregnant, not breastfeeding, and not planning on becoming pregnant during the course of the study;
  • Willingness to comply with all study intervention and follow-up procedures;
  • Ability to speak English or Spanish; and
  • Ability to provide informed consent.

Exclusion Criteria:

  • Inability to understand or an unwillingness to sign a written informed consent document;
  • Any significant toxic side effects related to first or second dose of doxorubicin/cyclophosphamide chemotherapy or biologic therapy that did not resolve to less than a CTCAE 3.0 grade 3 non-hematological toxicity;
  • Currently using any investigational agent;
  • Unstable or severe intercurrent medical condition that, in the opinion of the investigator, might interfere with the participant's ability to follow the protocol or achieve study objectives;
  • Psychological or sociological conditions, addictive disorders, or family problems that would preclude adherence with study drug or compliance with the protocol
  • Women who report pregnancy, are breast feeding, or have a positive pregnancy test;
  • Use of CoQ10 supplement use within 30 days of initiating study drug;
  • Use of over-the-counter nutritional vitamin greater than 5x RDA;
  • Fish allergy (due to fish-based softgel shell);
  • Currently taking FDA cardioprotective drugs, such as Zinecard (dexrazoxane);
  • History of chronic hepatitis B, hepatitis C, and HIV infection;
  • Problems swallowing oral medications due to prolonged emesis, mucositis, esophageal dysfunction, etc.; and,
  • Currently taking any form of antioxidant supplements while on study.
  • Use of warfarin.
  • Kosher (due to fish-based softgel shell)
  • Dietary restriction of tilipia (due to tilipia fish-based softgel shell)
  • Titanium Dioxide allergy (due to the opaque coloring used in the softgel).

Trial Contact Information

Trial Lead Organizations/Sponsors

Heather Greenlee, PhD, ND

  • National Cancer Institute
Heather Greenlee, Principal Investigator
Herbert Irving Comprehensive Cancer Center Clinical Research Management Office
Ph: 212-305-8615

Trial Sites


New York
New York

Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center

Heather Greenlee
Principal Investigator

Dawn Hershman

Katherine Crew, MD, MS

Matthew Maurer, MD

Serge Cremers, PharmD, PhD

Kevin Kalinsky

Link to the current record.
NLM Identifier NCT00976131 processed this data on October 20, 2014

Note: Information about this trial is from the database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the record to standardize the names of study sponsors, sites, and contacts. only lists sites that are recruiting patients for active trials, whereas lists all sites for all trials. Questions and comments regarding the presented information should be directed to